TOTAL SYNTHESIS OF OF4949-III, A NOVEL INHIBITOR OF AMINOPEPTIDASE B

Shigeru Nishiyama, Yoshikazu Suzuki, and Shosuke Yamamura* Department of Chemistry, Faculty of Science and Technology, Keio University, Hiyoshi, Yokohama, Japan

<u>Summary</u>: A novel aminopeptidase B inhibitor (OF4949-III) has been synthesized from Nbenzyloxycarbonyl-3,5-dibromo-L-tyrosyl-L-asparaginyl-3,4-dichloro-L-tyrosine methyl ester, whose oxidation with thallium trinitrate (TTN) as a key step followed by zinc reduction affords the corresponding diphenyl ether with the same heterocyclic skeleton as that of OF4949-III.

Four novel aminopeptidase B inhibitors represented by 0F4949-I (1) have been isolated from the culture broth of a fungus, <u>Penicillium rugulosum</u> 0F4949,¹ and their stereostructures have been also elucidated on the basis of some chemical evidence together with an X-ray crystallographic analysis of the monobromo derivative of 0F4949-I.² Quite recently, a novel inhibitor of angiotensin-I converting enzyme (ACE), designated K-13, has been isolated from the culture broth of <u>Micromonospara halophytica subsp. exilisia</u> K-13,³ and its structure (2) has been also determined by spectral and chemical studies of K-13 and its derivatives.⁴ These two antibiotics, 0F4949-I and K-13, are quite similar to each other in their structures. Interestingly, however, their cyclization modes are different around a diphenyl ether moiety. In connection with our synthetic study on tyrosine-derived metabolites,⁵ we are interested in these antibiotics because of their unique structures and a variety of physiological activities.^{3,6} We describe herein a total synthesis of 0F4949-IIII(3).





L-Tyrosine was treated with Cl_2 in MeOH (0 °C - room temp., overnight) and then esterified with 2,2-dimethoxypropane (room temp., 4 days) to afford 3,5-dichloro-L-tyrosine methyl ester (4),⁷ in almost quantitative yield, which was connected to N-<u>t</u>-butoxycarbonyl-L-asparagine using DCC (1.1 equiv.) - 1-hydroxybenzotriazole(1 equiv.) - N-methylmorpholine (1 equiv.) in DMF (0 °C - room temp., overnight) and then treated with HC1 in dioxane (room temp., 1.5 h) to give rise to the corresponding dipeptide (5)⁷ in 99% yield. According to essentially the same procedure as described above, the desired tripeptide (6)⁷ was further produced, in <u>ca</u>. 60% yield, from 5 and N-benzyloxycarbonyl-3,5-dibromo-L-tyrosine.

In the next step, the tripeptide (6) so far obtained was oxidized with TTN (3 equiv.)⁵ in MeOH (0 °C - room temp., overnight) to afford the desired cyclization product (7),⁸ in <u>ca</u>. 25% yield,⁹ which was subjected to zinc reduction in AcOH - THF (0 °C - room temp., overnight) followed by methylation with an excess amount of diazomethane in MeOH (room temp., 5 min) to give rise to the corresponding diphenyl ether (8)⁷ in 72% yield. This diphenyl ether (8) was further subjected to catalytic hydrogenation $[H_2/Pd-black$ in THF containing conc.HCl (room temp., overnight)]¹⁰ followed by reprotection using (BOC)₂0 (1.5 equiv.) - Et₃N (1.5 equiv.) in dioxane (room temp., 3 h) to afford a N-t-butoxycarbonyl compound (9)⁷ in 66% yield. Finally, this compound (9) was subjected to catalytic hydrogenation $[H_2/Pd-black$ in MeOH containing NaOAc (3 equiv.) (room temp., 2 days)] to afford a diphenyl ether (10).⁷ in 99% yield, which was hydrolyzed with 1N NaOH (1.2 equiv.) (room temp., 10 min), deprotected with HCl (30 equiv.) (room temp., overnight), and then neutralized with 1N NaOH to give rise to



the desired tripeptide,¹¹ in 77% overall yield, which was completely identical with natural OF4949-III (1) in all respects of spectral data (IR and ¹H NMR). Further synthetic study on K-13 (2) is in progress.

The authors wish to thank Drs. Susumu Sano and Kaoru Katayama (Central Research Laboratories, Takara Shuzo Co. Ltd.) for providing them an authentic sample of OF4949-III. They are also indebted to Dr. Yutaka Hashimoto (Research Laboratories, Pharmaceuticals Group, Nippon Kayaku Co. Ltd.) for measurement of FAB-mass spectra. This research has been supported in part by grants from the Ministry of Education, Science and Culture as well as from the Kawakami Memorial Foundation, to which grateful acknowledgment is made.

References

- S. Sano, K. Ikai, H. Kuroda, T. Nakamura, A. Obayashi, Y. Ezure, and H. Enomoto, J. Antibiot., 39, 1674 (1986).
- S. Sano, K. Ikai, K. Katayama, K. Takesako, T. Nakamura, A. Obayashi, Y. Ezure, and H. Enomoto, J. Antibiot., 39, 1685 (1986).
- 3. H. Kase, M. Kaneko, and K. Yamada, J. Antibiot., 40, 450 (1987).
- 4. T. Yasuzawa, K. Shirahata, and H. Sano, J. Antibiot., <u>40</u>, 455 (1987).
- H. Noda, M. Niwa, and S. Yamamura, Tetrahedron Lett., <u>22</u>, 3247 (1981); S. Nishiyama and S. Yamamura, <u>ibid.</u>, <u>23</u>, 1281 (1982); S. Nishiyama, T. Suzuki, and S. Yamamura, Chem. Lett., <u>1982</u>, 1851; S. Nishiyama and S. Yamamura, Bull. Chem. Soc. Jpn., <u>58</u>, 3453 (1985); S. Nishiyama, K. Nakamura, Y. Suzuki, and S. Yamamura, Tetrahedron Lett., <u>27</u>, 4481 (1986); S. Yamamura, S. Nishiyama, T. Inoue, I. Umezawa, M. Yuasa, and T. Inaba, Japan Kokai in press (1986).
- S. Sano, H. Kuroda, M. Ueno, Y. Yoshikawa, T. Nakamura, and A. Obayashi, J. Antibiot., 40, 512 (1987); ibid., 519 (1987).
- 7. The spectral data for the new compounds are in accord with the structures assigned, and only selected data are cited: 4: mp 103.5 - 106.5 °C; C10H11N03Cl2.HCl [m/z 265(M⁺ -HC1)]; IR (Nujol) 1750 cm⁻¹; δ (CD₃OD) 3.80(3H, s) and 7.18(2H, s). <u>5</u> as amorphous powder: C14H17N305C12·HC1 [m/z 378(M+ - C1)]; IR (Nujol) 1725, 1670, 1620, and 1560 cm⁻¹; δ (CD₃OD) 3.68(3H, s) and 7.15(2H, s). 6: mp 214 - 217 °C; [κ]²⁴ +5.76° (c 1.03, DMSO); IR (Nujol) 3400, 3270, 1725, 1690, 1640, and 1525 cm⁻¹; S (DMS0-d₆) 2.87 - 3.00(4H, complex), 3.62(3H, s), 3.92 - 4.12(2H, complex), 4.97(2H, br.s), 7.15(2H, s), 7.27(5H, s), and 7.43(2H, s). The molecular ion peak has not been detected in its mass spectrum, but the structure is supported by the other spectral data. g: mp 149 - 151 °C; $[\mathcal{A}]_{D}^{26}$ +39.1° (c 0.41, MeOH); C₃₂H₃₁N₄O₉Cl₂Br [m/z 767(M⁺ + 1)]; IR (film) 3325, 3100, 1730, 1660, 1560, and 1490 cm⁻¹; δ (CDCl₃) 2.18 - 2.61(2H, complex), 2.83(1H, br.d, J = 13.7 Hz), 3.08(1H, br.d, J = 10.5 Hz), 3.33(1H, dd, J = 13.4, 3.9 Hz), 3.81(3H, s), 4.01(3H, s),4.47(1H, br.s), 4.59(1H, br.s), 4.88 - 4.94(1H, m), 5.10(1H, d, J = 12.2 Hz), 5.19(1H, d, J = 12.2 Hz), 5.63 - 5.65(2H, complex), 5.72(1H, br.s), 6.89(1H, br.s), 7.16(1H, br.s), and 7.30 - 7.38(6H, complex). 9: mp 159 - 164 °C; [4]²⁶ +43.4° (c 0.14, MeOH); IR (film) 1740 cm⁻¹; δ (CD₂OD) 1.48(9H, s), 3.77(3H, s), 3.95(3H, s), 5.70(1H, d, J = 2.1 Hz), 6.85(1H, d, J = 2.1 Hz), 7.27(1H, d, J = 2.7 Hz), and 7.57(1H, d, J = 2.7 Hz). These spectral data support the assigned structure, although the molecular ion peak has not

been detected in its mass spectrum. 10: mp 163 - 164 °C; $[\checkmark]_D^{27}$ +50.8° (c 0.03, MeOH); C₂₉H₃₆N₄O₉ [m/z 585(M⁺ + 1)]; IR (film) 3300, 1730, 1660, 1540, and 1500 cm⁻¹; δ (CD₃OD) 5.88(1H, d, J = 2.4 Hz), 6.61(1H, dd, J = 8.5, 2.4 Hz), 6.87(1H, dd, J = 8.5, 2.4 Hz), 6.92(1H, d, J = 8.5 Hz), 6.99(1H, dd, J = 8.5, 2.4 Hz), 7.19(1H, dd, J = 8.5, 2.4 Hz), and 7.37(1H, dd, J = 8.5, 2.4 Hz).

- 8. Although the oxidation product (7) was unable to be purified completely, its structure was confirmed by its ¹H NMR spectrum: \mathcal{S} (acetone-d₆) 3.16(3H, s), 3.67(3H, s), 5.30(1H, br.s), 7.21 7.37(7H, complex), and 7.49(1H, br.s).
- 9. Such a cyclization product as K-13 (2) has not yet been obtained.
- 10. Although reductive removal of the three halogen atoms has been attempted together with the N-benzyloxycarbonyl group, any good result has not yet been obtained.
- 11. The optical rotation of natural OF4949-III has not been reported. The synthetic sample shows the negative optical rotation ($[\mathcal{L}]_D^{27}$ -38.2° (c 1.06, 0.1N HCl)) similar to that of OF4949-1 (1).

(Received in Japan 26 October 1987; accepted 30 November 1987)